Avacta Group’s (AVCT) “Buy” Rating Reiterated at Peel Hunt

Peel Hunt restated their buy rating on shares of Avacta Group (LON:AVCT) in a research note issued to investors on Monday, MarketBeat Ratings reports. Peel Hunt currently has a GBX 99 price target on the biotechnology company’s stock.

Avacta Group Stock Performance

LON AVCT opened at GBX 69.16 on Monday. The firm has a 50-day moving average of GBX 55.91 and a 200-day moving average of GBX 42.37. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29. The stock has a market cap of £282.36 million, a PE ratio of -394.07 and a beta of 1.12. Avacta Group has a 52-week low of GBX 26 and a 52-week high of GBX 75.

Avacta Group (LON:AVCT) last posted its earnings results on Tuesday, September 30th. The biotechnology company reported GBX (4.46) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. On average, sell-side analysts anticipate that Avacta Group will post -9.9011833 EPS for the current year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).